Clinical Trials Logo

Migraine Disorders clinical trials

View clinical trials related to Migraine Disorders.

Filter by:

NCT ID: NCT03076515 Terminated - Acute Migraine Clinical Trials

Migraine Treatment With Nerivio Migra Neurostimulation Device

Start date: April 2, 2017
Phase: N/A
Study type: Interventional

This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.

NCT ID: NCT03022838 Terminated - Migraine Clinical Trials

The Effects of Caffeine Withdrawal on Migraine

Start date: February 28, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Sporadic and chronic dietary consumption of caffeine has substantial biological effects on the nervous system. The effects on migraine are at large not known. In this study we want to assess the effects of caffeine withdrawal on migraine.

NCT ID: NCT02991430 Terminated - Intervention Clinical Trials

A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache

Start date: June 30, 2017
Phase: N/A
Study type: Interventional

This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.

NCT ID: NCT02972502 Terminated - Headache, Migraine Clinical Trials

Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department

Start date: February 2014
Phase: Phase 4
Study type: Interventional

Metoclopramide (Reglan) is a common agent used for relief of headaches in the emergency department (ED).In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of medication, is thought to act by affecting the dopamine 2 receptor in the brain. By exploring haloperidol as an option for treatment, the investigators hope to discover a more efficient and effective medication for the treatment of non-traumatic headaches, thereby decreasing a patient's length of stay in the department and decreasing the rate of return visits for continued discomfort from the same headache. This study could lead to the increased usage of haloperidol as a first line agent in the treatment of prolonged headaches presenting to the ED.

NCT ID: NCT02964741 Terminated - Migraine Clinical Trials

Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)

Start date: February 22, 2017
Phase: N/A
Study type: Interventional

This study investigates whether non-invasive brain stimulation, given for 20 minutes/once per day for ten days (M-F) can reduce migraine pain. Thirty patients will receive this treatment, while thirty will receive a "sham" procedure. Up to thirty healthy volunteers will be asked to undergo baseline assessments only (imaging, but no brain stimulation). Healthy volunteer data may be used from a prior study (NINDS-K23062946 project [IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator]).

NCT ID: NCT02758990 Terminated - Obesity Clinical Trials

Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

Start date: March 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized medical equipment in order to develop lifestyle recommendations tailored to individual genetics for a host of common chronic health conditions.

NCT ID: NCT02720211 Terminated - Clinical trials for Headache Migraine Chronic

Spectacle Tints and Thin-Films for Migraine

Start date: August 2016
Phase: N/A
Study type: Interventional

Nearly all migraine sufferers report sensitivity to light during a headache and a significant proportion of sufferers report light sensitivity between attacks. Light is also a common trigger for migraine headaches. Spectacle lenses that have been treated with tints and spectacle lenses that have been treated with thin-films have both been shown to reduce light sensitivity and headache in patients with migraine. At this time, it is not clear which spectacle lens treatment is superior. The purpose of this trial is to determine if there's a significant, therapeutic advantage to either spectacle lens treatment. Both treatments could be a novel, non-invasive adjuvant in the treatment of migraine.

NCT ID: NCT02630719 Terminated - Migraine Clinical Trials

Timolol Eye Drops in the Treatment of Acute Migraine Headache

Start date: January 2016
Phase: N/A
Study type: Interventional

The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.

NCT ID: NCT02492295 Terminated - Migraine Headache Clinical Trials

Low-dose Propofol for the Treatment of Severe Refractory Migraine Headache in the Emergency Department

Start date: August 2014
Phase: N/A
Study type: Interventional

Migraine headache is a frequent Emergency Department complaint. While first-line Emergency Department treatment for this condition is well-established, optimal second-line treatment options are not well-defined. First line Emergency Department treatments include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), dopamine antagonists. Second line treatments that have been proposed include triptans, steroids, antiepileptics, benzodiazepines, magnesium and narcotics, but none have shown reliable Emergency Department efficacy (less than 50% in most studies). In the past ten years there have been several case series published on using low, sub-anesthetic doses of propofol for the treatment of refractory migraine. These case series have reported very impressive efficacy rates, especially in comparison to the published efficacy rates of other second-line treatments. Personal experience using this treatment modality has also yielded impressive clinical results. Most of the published series, however, have not been conducted in the Emergency Department. The Investigators propose to conduct a prospective, observational trial of low-dose propofol for the treatment of refractory migraine in the Emergency Department. Propofol is a frequently-used Emergency Department sedative, with a good safety profile when administered by experienced Emergency Medicine practitioners using appropriate monitoring. The primary outcome measurement will be reduction of pain after treatment, with secondary outcome measures related to the safety of treatment and continuation of pain relief after leaving the Emergency Department. Although the protocol will involve the use of low-dose propofol with the aim of achieving light-to-moderate sedation only, all patients will care for and monitor at a level appropriate for deep procedural sedation.

NCT ID: NCT02375789 Terminated - Migraine Headache Clinical Trials

Intranasal Cooling for Symptomatic Relief of Migraine

COOLHEAD2
Start date: October 2015
Phase: N/A
Study type: Interventional

This study will be a randomised placebo controlled trial examining the effectiveness of using an intranasal cooling device (the RhinoChill) in providing relief of pain and symptoms of acute migraine. It will involve using two nasal catheters to cool the nasal cavity which provides localised cooling of the local nasal tissue and the blood vessels which supply blood to the brain. This cooling effect will cause the blood vessels to constrict as well as stimulating special cold receptors that are thought to be involved in the relief of migraine, thereby providing both pain and associated symptomatic relief. Ninety patients will be randomised in a 1:1 fashion, clustered to three different recruitment sites. The patients will have a 30 day period of data collection for their current migraine frequency, treatment and response to medication (with a minimum of 2 migraine attacks recorded) before starting the treatment phase with the RhinoChill Device. Treatment will be for 2 migraine attacks. Only a single treatment is allowed for the first attack, but on the second attack the patient may deliver 2 treatments with a gap of at least 2 hours between treatments.